Genovis Acquires KPL
We are expanding our enzyme platform with a proprietary portfolio of precision proteases for protein analysis
Making Scientists Move Faster
We provide tools and technologies that streamline workflows
– from scientific discoveries to new medicines
Featured
Online Ordering Now Available Across Europe
Our new European e-commerce platform is live! Customers in Europe can now order SEQguard directly online or submit purchase orders (POs) through the store.
Download LysCERATOR Poster from ASMS 2026
A Novel Lysine-specific Protease with Superior Digestion Efficiency
The Sanofi Analytical Symposium
Frankfurt, Germany
June 17, 2026Event
About Genovis
We offer customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics.
Our enzyme products, SmartEnzymes™, are a unique selection of rapid and easy-to-use enzymatic tools designed to improve the efficacy and throughput in analytical or preparative workflows for complex biopharmaceuticals. The enzymes are used by scientists all over the world and the innovative product formats facilitate the characterization, development, production, and quality control of biological drugs.
Products
Applications
Our products support a wide range of applications across biopharma, biotechnology, academic research, and genomics – helping scientists gain deeper insight into their molecules and products.
From enzyme solutions for protein characterization and glycan analysis to tools for bioconjugation, glycan remodeling, and nucleic acid workflows, our technologies are designed to support key analytical and development processes – particularly in mass spectrometry. Across both protein and genomic applications, we help simplify complex workflows, improve data quality, and enable more comprehensive characterization of biological systems.
Explore our applications to see how our solutions can support your research and development.
Services
News
TCRVβ2-Targeted ADCs Show Promise for Precision T Cell Cancer Therapy
Genovis Acquires KPL
Digested Guide to ASMS 2026
A New Standard in Lys-C Digestion: Introducing LysCERATOR™
Benchmarking Study Establishes SEQURNA® as a Superior, DTT-Free, RNase Inhibitor for High-Sensitivity Single-cell RNA-seq
TCRVβ2-Targeted ADCs Show Promise for Precision T Cell Cancer Therapy
A recent study published in Blood Advances demonstrates how site-specific antibody-drug conjugates (ADCs) targeting TCRVβ2 can selectively eliminate malignant T cells while sparing most healthy T cells. Using our GlyCLICK® technology, the researchers generated homogeneous anti-TCRVβ2 ADCs with defined drug-to-antibody ratios and potent anti-tumor activity both in vitro and in vivo. Patients with advanced cutaneous…
Events
The Sanofi Analytical Symposium
Frankfurt, Germany
Antibody Industrial Symposium
Montpellier, France